DLB

BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...

BOSTON, July 14, 2026 CervoMed presented new clinical, plasma biomarker, pharmacokinetic, and imaging analyses at the Alzheimer’s Association International...

BOSTON, July 6, 2026 CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented...

BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...